📜 Post with us on Reddit
📝 Create a new article
🏭 Create a company page
🇬🇧 - in English
🇫🇷 - en Français (FR)
🇵🇹 - em Português (PT)
🇩🇪 - auf Deutsch (DE)
🇯🇵 - 日本語で (JA)
Sponsored articles

You can edit almost every page by Creating an account and confirming your email.

Rupert Martin Bauersachs

From EverybodyWiki Bios & Wiki



Rupert Martin Bauersachs is a German vascular physician and internist, director of the Department of Vascular Medicine - Angiology at the Darmstadt Hospital and Professor at the Goethe University Frankfurt.

Life

Bauersachs studied medicine at the Ludwig Maximilian University of Munich and the Technical University of Munich from 1977 to 1983, at the Oxford University Medical School 1981. In 1984 he received his MD. From 1984 to 1985 he was post-doc Research Fellow at the Institute of Pharmacology of the Technical University of Munich and from 1985 to 1987 Research Fellow of the American Heart Association at the Department of Physiology and Biophysics of the University of Southern California Los Angeles. He completed a specialist training as an internist at the Klinikum München-Bogenhausen from 1987 to 1993 and received his specialist training in angiology, diabetologist, phlebologist and hemostaseologist at the Goethe University Frankfurt and the University of Mainz from 1993 to 1999. In 1999, he completed his habilitation on ischemia and reperfusion disorders and obtained a postgraduate degree in angiology. In 1999, he was recognized as a Fellow of the International Union of Angiology.[1]

Bauersachs took over the provisional head of the Department of Vascular Medicine of the Goethe University Frankfurt am Main from 1999 to 2003 and co-founded the first German university vascular center at the Goethe University Frankfurt in 2000. He was appointed director of the Department of Angiology, Darmstadt Hospital and co-founder of the Darmstadt Vascular Center in 2003. In 2004 Bauersachs received an unscheduled professorship at the Goethe University Frankfurt and a visiting professorship Vulnerable individuals and populations - VIP at the Center for Thrombosis and Hemostasis (CTH) of the University of Mainz in 2012.[1][2]

He is the scientific director of the Action Alliance Thrombosis,[3] which he co-initiated in 2014, and which organizes the World Thrombosis Day in Germany.[4]

Clinical focuses

Clinical-scientific contribution

Bauersachs propagated outpatient treatment of deep vein thrombosis in the late 1990s[5][6] and ten years later the acute treatment and prolonged secondary prevention of venous thrombosis with directly acting oral anticoagulants (DOACs) [7]. Again, ten years later the HOT-PE study group with Bauersachs showed that home treatment or early discharge of pulmonary embolism with DOACs is safe and effective. [8] For the first time, a research team with Bauersachs studied a new anticoagulant target by inhibiting coagulation factor XIa with Osocimab. Osocimab was comparable with enoxaparine and superior if administered preoperatively. [9] For the neglected clinical entity of superficial venous thrombosis (thrombophlebitis), a team with Bauersachs could establish an evidence-based therapy for this common clinical picture in 2010.[10][11] For vulnerable thrombosis populations, including pregnant women, the elderly, renal insufficiency or cancer, Bauersachs was able to lead or co-design new studies that produced guideline-relevant results.[12][13][14][15][16][17][18][19] Together with William Hiatt Bauersachs chaired the Voyager study, a randomized controlled trial, which prospectively studied the antithrombotic management after vascular surgery or intervention in patients with peripheral arterial disease. The vascular dose of (→) rivaroxaban together with (→) aspirin showed a reduction of limb and cardiovascular complications; however, bleeding rates were increased compared to aspirin alone.[20]

Critical implementation of the research results in clinical practice is a concern to him, also with the aim to avoid over- and undertreatment, for example in thrombophilia,[21] use of oral contraceptives,[22] diagnosis of thrombosis[23] including gender-specific aspects,[24] quality of care,[25][26] and patient preference,[27][28] as well as in complex perioperative management.[29][30][31][32] Bauersachs is specifically concerned with awareness for vascular diseases, patient quality of life and patient information, for example in deep vein thrombosis,[33][34], pulmonary embolism [34][35] or peripheral arterial disease.[36]. As scientific director of the Action Alliance Thrombosis,[37] he was instrumental in the development of an easy-to-use algorithm for the complex investigation of anticoagulation time in venous thromboembolism ("anticoagulation traffic light system").[38] [39]. Bauersachs is involved in several national and international guidelines and position statement papers for thrombosis management during pregnancy, for oral contraception, for perioperative anticoagulation, for the antiphospholipid syndrome, for carotid artery stenosis, peripheral arterial disease and other vascular disorders.. [40][41][42][43][44][45][46][47]

Memberships

  • Council board member of the German Society of Angiology[48]
  • Council board member of the German Society for Phlebology

Publications

References

  1. ↑ 1.0 1.1 "Rupert Martin Bauersachs CV Deutsche Gesellschaft für Phlebologie".
  2. ↑ "Gastwissenschaftler- cth-mainz.de". www.unimedizin-mainz.de.
  3. ↑ "Aktionsbündnis - Startseite Risiko Thrombose". www.risiko-thrombose.de. Archived from the original on 2018-12-30. Retrieved 2020-11-14.
  4. ↑ "Welt-Thrombose-Tag - Startseite Risiko Thrombose". www.risiko-thrombose.de.
  5. ↑ Bauersachs R, Lindhoff-Last E, Wolff U, Ehrly A: Aktuelles Management der tiefen Venenthrombose. Med Welt 1998 1998; 49: 194-214
  6. ↑ Bauersachs RM, Lindhoff-Last E, Ehrly AM: [Ambulatory treatment of an acute pulmonary artery embolism in fresh thigh vein thrombosis using low-molecular-weight heparin]. Dtsch Med Wochenschr 1999; 124: 1485-1488
  7. ↑ Bauersachs R, Berkowitz SD, Brenner B, et al: Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510
  8. ↑ Barco S, Schmidtmann I, Ageno W, et al: Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. Eur Heart J 2020; 41: 509-518.
  9. ↑ Weitz JI, Bauersachs R, Becker B, et al: Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA 2020; 323: 130-139.
  10. ↑ Décousus H, Leizorovicz A, Bauersachs R, et al: Fondaparinux for the treatment of superfical-vein thrombosis in the legs N Engl J Med 2010; 363: 1222-1232
  11. ↑ Beyer-Westendorf J, Schellong SM, Gerlach H, et al: Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol 2017; 4: e105-e113
  12. ↑ Bauersachs RM, Dudenhausen J, Faridi A, et al: Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 2007; 98: 1237-1245
  13. ↑ Leizorovicz A, Siguret V, Mottier D, et al: Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep(R) in Renal Insufficiency Study (IRIS). Thromb Res 2011; 128: 27-34
  14. ↑ Lee AY, Bauersachs R, Janas MS, et al: CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer 2013; 13: 284
  15. ↑ Bauersachs R, Lee AYY, Kamphuisen PW, et al: Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study. Thromb Haemost 2018; 118: 914-921
  16. ↑ Schellong SM, Gerlach HE, Tebbe U, et al: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: An analysis of the CERTIFY study. Thromb Res 2011; 128: 417-421
  17. ↑ Bauersachs R, Schellong SM, Haas S, et al: CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thromb Haemost 2011; 105:
  18. ↑ Bauersachs RM: Guidelines for the management of cancer and thrombosis - Special aspects in women. Thromb Res 2015; 135 Suppl 1: S16-22
  19. ↑ Agnelli G, Becattini C, Meyer G, et al: Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. New England Journal of Medicine 2020.
  20. ↑ Bonaca MP, Bauersachs RM, Anand SS, et al: Rivaroxaban in Peripheral Artery Disease after Revascularization. New England Journal of Medicine 2020:
  21. ↑ Bauersachs R, Kuhl H, Lindhoff-Last E, Ehrly AM: [Risk of thrombosis with oral contraceptives: value of a thrombophilia screening test]. Vasa 1996; 25: 209-220
  22. ↑ Beyer-Westendorf J, Bauersachs R, Hach-Wunderle V, Zotz RB, Rott H: Sex hormones and venous thromboembolism - from contraception to hormone replacement therapy. Vasa 2018; 47: 441-450
  23. ↑ Schellong S, Gerlach H, Hach-Wunderle V, et al: Diagnosis of Deep Vein Thrombosis: Adherence to guidelines and outcomes in real world health care. Thrombosis and Hemostasis 2009; 102: 1234-1240
  24. ↑ Bauersachs RM, Riess H, Hach-Wunderle V, et al: Impact of gender on the clinical presentation and diagnosis of deep vein thrombosis. Thromb Haemost 2010; 103: 710-717
  25. ↑ Mueller S, Pfannkuche M, Breithardt G, et al: The quality of oral anticoagulation in general practice in patients with atrial fibrillation. Eur J Intern Med 2014; 25: 247-254
  26. ↑ Boettger B, Wehling M, Bauersachs R-, Amann S, Wilke T: Initial anticoagulation therapy in patients with venous thromboembolism and impaired renal function: results of an observational study J Public Health 2014:
  27. ↑ Bottger B, Thate-Waschke IM, Bauersachs R, Kohlmann T, Wilke T: Preferences for anticoagulation therapy in atrial fibrillation: the patients' view. J Thromb Thrombolysis 2015:
  28. ↑ Wilke T, Bauer S, Mueller S, Kohlmann T, Bauersachs R: Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review. Patient 2017; 10: 17-37
  29. ↑ Bauersachs RM, Schellong S, Haas S, et al: Perioperative Bridging of Oral Anticoagulation Therapy. Dtsch Arztebl 2007; 104: 1237-1244
  30. ↑ Bauersachs RM, Gogarten W, Hach-Wunderle V, et al: [Perioperative management of anticoagulation with Rivaroxaban]. Klinikarzt 2012; 41: 424–431
  31. ↑ Schellong SM, Riess H, Spannagl M, et al: [Bridging anticoagulation in patients receiving vitamin K antagonists: Current status]. Anaesthesist 2018; 67: 599-606
  32. ↑ Omran H, Bauersachs R, Rubenacker S, Goss F, Hammerstingl C: The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost 2012; 108: 65-73
  33. ↑ Monreal M, Agnelli G, Chuang LH, et al: Deep Vein Thrombosis in Europe-Health-Related Quality of Life and Mortality. Clin Appl Thromb Hemost 2019; 25: 1076029619883946
  34. ↑ 34.0 34.1 Chuang LH, Cohen AT, Agnelli G, et al: Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis. Qual Life Res 2019; 28: 1155-1177
  35. ↑ Chuang LH, van Hout B, Cohen AT, et al: Deep-vein thrombosis in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. Thromb Res 2018; 170: 165-174
  36. ↑ Bauersachs R, Debus S, Nehler M, et al: A Targeted Literature Review of the Disease Burden in Patients With Symptomatic Peripheral Artery Disease. Angiology 2019: 3319719896477
  37. ↑ "Startseite Aktionsbündnis Thrombose - Startseite Risiko Thrombose". www.risiko-thrombose.de.
  38. ↑ Bauersachs R: [Prolonged Secondary Prevention After Venous Thromboembolism]. Dtsch Med Wochenschr 2018; 143: 137-142
  39. ↑ Weitz JI, Lensing AW, Prins MH, et al: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med 2017; 376: 1211-1222
  40. ↑ Mazzolai L, Aboyans V, Ageno W, et al: Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European society of cardiology working groups of aorta and peripheral circulation and pulmonary circulation and right ventricular function. Eur Heart J 2017:
  41. ↑ Hart C, Bauersachs R, Scholz U, et al: Prevention of VTE during Pregnancy and the Puerperium with a Special Focus on Women with Hereditary Thrombophilia or Prior VTE – Position Paper of the Working Group in Women’s Health of the GTH. Hämostaseologie 2020; 40:
  42. ↑ Linnemann B, Bauersachs R, Rott H, et al: Diagnosis of pregnancy-associated venous thromboembolism - position paper of the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH). Vasa 2016; 45: 87-101
  43. ↑ Linnemann B, Scholz U, Rott H, et al: Treatment of pregnancy-associated venous thromboembolism - position paper from the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH). Vasa 2016; 45: 103-118
  44. ↑ Stute P, Kiesel L, Bauersachs R, Beyer-Westendorf J, Bühling K: Hormonal Contraception. Guideline of the German Society of Gynecology and Obstetrics (S3-Level, AWMF Registry No. 015/015, December 2018). Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften eV (AWMF) 2019:
  45. ↑ Bauersachs R, von Heymann C, Kemkes-Matthes B, et al: Blutungsrisiko und Nierenfunktion bestimmen das Vorgehen: Empfehlungen zum perioperativen Umgang mit direkten oralen Antikoagulanzien (DOAKs) und thrombozytenaggregationshemmenden Substanzen. Dtsch Arztebl 2019; 116. : A 1894-1898:
  46. ↑ Bauersachs R, Langer F, Kalka C, et al: Treatment of the antiphospholipid syndrome with direct oral anticoagulantsPosition statement of German societies. Vasa 2019; 48: 483-486:
  47. ↑ Pastori D, Eikelboom JW, Anand SS, et al: Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. Thromb Haemost 2019; 119: 576-585:
  48. ↑ "DGA - Beirat". www.dga-gefaessmedizin.de.

External links



This article "Rupert Martin Bauersachs" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Rupert Martin Bauersachs. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.


Retrieved from "https://en.everybodywiki.com/index.php?title=Rupert_Martin_Bauersachs&oldid=6162146"
License CC BY-SA 3.0
Powered by MediaWiki